News | Nuclear Imaging | December 22, 2020

Team brings a new tool for alpha therapy by developing a paired isotope option for PET scans

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.


December 22, 2020 — Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a paired analogue of actinium and thorium that can be imaged using positron emission tomography (PET). Establishing a routine production pathway for cerium-134 is an essential step in advancing the use of the alpha emitters for cancer therapy.

“This advancement offers new possibilities for medical staff and drug developers to better characterize new actinium and thorium therapeutics,” said Stosh Kozimor, lead Los Alamos National Laboratory researcher on the joint project with Lawrence Berkeley National Laboratory, the University of California, and the University of Wisconsin.

Targeted alpha therapies using actinium and thorium radionuclides are emerging as effective treatments for diseases such as cancer, with the potential to treat patients with little to no negative side-effects. But methods to image the radionuclides’ location inside the body are needed to continue the development towards final safe and effective pharmaceuticals. The key to this research is that cerium-134 can be attached to the same chelate/ligand (transport agent which is attracted to diseased cells, e.g. tumors) as the actinium-225 and thorium-227, so that the therapeutic and the diagnostic behave the same. The cerium emits a positron that can be detected with PET and shows where the therapeutic is in the body, identifying its proximity to the diseased tissue in question.

“These promising alpha-emitting isotopes for targeted alpha therapy, actinium-225 and thorium-227, are incompatible with PET imaging, which is essential to studying their therapeutic effect in the body. We overcame this obstacle by developing large-scale production and purification methods for cerium-134, and demonstrating its efficacy in PET for imaging these alpha emitters,” said Kozimor. “This demonstration is an important step toward making this isotope routinely available for clinical use.” The cerium-134, as well as actinium-225 and thorium-229, are available from the DOE Isotope Program

The paper: Bailey, T.A., Mocko, V., Shield, K.M. et al. Developing the 134Ce and 134La pair as companion positron emission tomography diagnostic isotopes for 225Ac and 227Th radiotherapeutics. Nat. Chem. (2020). DOI 10.1038/s41557-020-00598-7

The funding: U.S. Department of Energy (DOE) Isotope Program, managed by the Office of Science for Isotope R&D and Production. Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, was supported by the DOE, Office of Science. Additional support from a DOE Integrated University Program graduate research fellowship and a Nuclear Regulatory Commission Faculty Development Grant.

For more information: www.lanl.gov

Related Content

News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
Feature | Magnetic Resonance Imaging (MRI) | Christine Book

August 10, 2022 — The imaging community has lost a legend, recognized for having revolutionized the field of diagnostic ...

Time August 10, 2022
arrow
News | Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
News | Radiology Business

August 4, 2022 — The Biden Administration, through the U.S. Department of Health and Human Services and the Centers for ...

Time August 04, 2022
arrow
News | Pediatric Imaging

August 3, 2022 — The Jack Martin Fund (JMF) has built on its partnership with the Mount Sinai Health System to provide ...

Time August 03, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
Subscribe Now